Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised